Insulet (Nasdaq:PODD) announced today that it appointed Eric Benjamin to the role of chief operating officer (COO), effective immediately. The Acton, Massachusetts-based automated insulin delivery system maker also appointed Manoj Raghunandanan as chief growth officer. In his expanded role, Benjamin now leads Insulet’s end-to-end growth and innovation engine. He sets the strategy and guides execution […]
Insulet
Insulet increases 2025 guidance on Q2 beats, 33% sales growth
Insulet (Nasdaq:PODD) shares ticked up before hours today on second-quarter results that came in ahead of the consensus forecast. Shares of PODD rose 13% to $$313.45 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $22.5 million. That equals 32¢ per share on sales of $649.1 million for […]
The 10 largest diabetes technology companies in the world
What has changed in the last year as diabetes technology developers continue to innovate and advance their offerings? We are seeing the industry form an intriguing niche at the intersection of medtech and consumer devices. Various companies around the world are delivering numerous options when it comes to the type of technology they want to […]
Insulet hires new chief HR officer from J&J
Insulet (Nasdaq:PODD) announced that it named Lisa Blair Davis as its new SVP and chief human resources officer. She joins the automated insulin delivery technology maker from Johnson & Johnson. There, she most recently served as VP of global human resources for Johnson & Johnson MedTech. SVP and Chief Medical Officer, Dr. Trang Ly, spoke […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Omnipod 5 rollout for type 2 advances as Insulet pursues next-gen automation
When it comes to the diabetes tech market, the Insulet (Nasdaq:PODD) Omnipod 5 automated insulin delivery system is nothing new. Omnipod 5 first received FDA clearance for individuals aged 6 years old and up with type 1 diabetes in January 2022. At that point, it became the world’s first available tubeless, wearable, automated insulin delivery […]
Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
Insulet (Nasdaq:PODD) announced today that it partnered with Marvel to launch a comic book featuring a hero with type 1 diabetes. The companies collaborated on the comic to help make people with diabetes feel seen, understood and represented. This marks another initiative for the Acton, Massachusetts-based automated insulin pump maker to promote inclusivity and representation. […]
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
Insulet (Nasdaq:PODD) today announced the compatibility of its Omnipod 5 App for iPhone with Dexcom G7 continuous glucose monitor (CGM). The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone. Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM, such as G7. It […]
Insulet stock rises on Street-beating Q1, 29% sales uptick
Insulet’s (Nasdaq:PODD) stock soared more than 20% today on first-quarter results that exceeded the consensus forecast. Shares of PODD were trading at around $307 a share near the close of trading, the day after the company’s evening earnings report. The Acton, Massachusetts–based automated insulin delivery technology maker reported profits of $35.4 million. That equals 50¢ per […]
Insulet earns insulin patch pump patent victory against EOFlow with permanent injunction
A judge has issued a permanent injunction, signaling an Insulet (Nasdaq:PODD) victory in a trade secret case against EOFlow. The permanent injunction highlights the successful defense of Insulet’s intellectual property. Subsequently, the damages award was reduced from $452 million to $60 million at Insulet’s election. The company wanted the permanent injunction instead of the higher […]
